Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
ASH 2020: Dr. Jennifer Brown on cardiovascular events in patients with chronic lymphocytic leukemia (CLL) treated with acalabrutinib
There has been much excitement about the possibility that BTK inhibitors such as ibrutinib or acalabrutinib might improve outcomes in COVID-19 for all patients ever since Dr. Treon published a retrospective
#2 At virtual ASCO 2020, Dr. John Byrd led a group of researchers to report the latest from the first phase 2 study of acalabrutinib, ACE-CL-001 (NCT02029443), a next-generation BTK inhibitor, which is now approved for CLL patients, both treatment-naïve as well as those with relapsed/refractory disease.
ASH 2019: Dr Deborah Stephens on ARQ 531, a reversible BTK inhibitor to treat CLL that is no longer responding to ibrutinib or acalabrutinib, and maybe more.
Getting a laboratory test result really has no meaning without having something with which to compare it. Its meaning comes from comparing it to reference values, which are the values expected for a group of otherwise healthy persons.
Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society
Dr. Brian Koffman, the Executive Vice President (EVP) and Chief Medical Officer (CMO) of the CLL Society, counts down his top ten CLL related abstract from ASCO or the American Society
For immediate release, Nov 21. 2019 U.S. Food and Drug Administration (FDA) Approves Acalabrutinib for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL / SLL) On November 21, 2019, the FDA announced that it had
Over the last 8 years helped lead the charge of new targeted therapies in chronic lymphocytic leukemia with the approval of ibrutinib. Ibrutinib is the first in class FDA approved oral targeted
One click to our most popular content.
